Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Related BIIB
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View
Illumina (ILMN) Tops Q2 Earnings & Revenues, Ups Guidance
Don't Panic Over Recent Tech Turmoil (Fox Business)
Related XNPT
XenoPort's XP23829 in Phase II Study - Analyst Blog
Xenoport, Inc. (XNPT) Soars: Stock Up 5.9% - Tale of the Tape

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Posted-In: Analyst Color News FDA Analyst Ratings


Most Popular

Related Articles (BIIB + XNPT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters